Abbott Aims To Get Nutritionals Back On Track In Wake Of Similac Recall
This article was originally published in The Tan Sheet
Executive SummaryAbbott says its nutrition business is on track for a return to full-scale production and growth after absorbing an expected $100 million hit to third-quarter sales from its September Similac recall
You may also be interested in...
Novartis begins OTC recovery with Excedrin; Abbott Nutrition up double digits in Q2; trade groups discuss supplement GMPs with Sen. Durbin; ChromaDex licenses patents for nicotinamide riboside; Nature Made supplements alleged to contain pork by-products; more news In Brief.
Mead Johnson forecasts slower growth in China; Abbott reclaims nutritional market share; Colgate expects product launches to drive 2012 growth